Worried About Moderna's Vaccine Revenue? Check Out These 2 Charts.
Moderna's (NASDAQ: MRNA) coronavirus vaccine revenue has been more than great so far. The company reported $18.5 billion in vaccine revenue last year. And the biotech predicts it will generate at least $21 billion in revenue this year; that's according to advance purchase agreements signed so far.
Still, investors are starting to worry about what's next. Experts say that COVID-19 could shift from pandemic to endemic as soon as this year. At that point, the coronavirus will continue to circulate -- but infection rates won't peak as they've been doing over the past two years. Does this mean Moderna's vaccine revenue is set to drop off a cliff? Let's check out the following charts for a couple of clues.
Image source: Getty Images.
Source Fool.com
